



OPEN ACCESS

Longitudinal study of correlates of modern contraceptive use and impact of HIV care programmes among HIV concordant and serodiscordant couples in Rakai, Uganda

Heena Brahmbhatt,¹ Fredrick Makumbi,² Tom Lutalo,³ Joseph Sekasanvu,⁴ David Serwadda,⁵ Maria J Wawer,⁶ Ronald H Gray⁷

For numbered affiliations see end of article.

Correspondence to

Dr Heena Brahmbhatt, Johns Hopkins Bloomberg School of Public Health, E4010, 615 North Wolfe Street, Baltimore, MD 21205, USA; hbrahmbh@jhsph.edu

Received 15 January 2013

Revised 13 May 2013

Accepted 29 June 2013

Published Online First

16 August 2013



Open Access
Scan to access more
free content



CrossMark

To cite: Brahmbhatt H, Makumbi F, Lutalo T, *et al.* *J Fam Plann Reprod Health Care* 2014;**40**:208–216.

ABSTRACT

Objective To assess trends and determinants of family planning use and impact of HIV serostatus among couples.

Methods Couples' data were retrospectively linked from cohort surveys in Rakai, Uganda between 1999 and 2011, and were classified by HIV status as concordant (M+F+/M-F-) or serodiscordant (M-F+/M+F-). HIV care (HIVC) was grouped into three periods, pre-antiretroviral therapy (pre-HIVC) (<2004), HIVC roll-out (2005–2007) and HIVC scale-up (≥2008). Trends in couple contraceptive use were assessed by chi-square test (χ^2) for trend, and multinomial logistic regression was used to estimate adjusted odds ratios (ORs) of predictors of contraceptive use.

Results A total of 6139 couples contributed 13 709 observations. Hormonal contraception (HC) use increased over time from 22.9% to 33.9%, $p<0.001$, with significant increases among M-F- (23.2% to 34.8%, $p<0.0001$) and M+F+ (20.8% to 32.2%, $p=0.0005$), but not serodiscordant couples. Condom use significantly increased among M+F+ (30.3% to 48.0%, $p<0.001$) and serodiscordant couples (24.2% to 48.7%, $p<0.001$), but not among M-F- couples. Dual use of HC and condoms increased over time, irrespective of HIV status. Factors associated with increases in contraceptive use were: higher education, co-resident children, male non-marital relationship and scaled-up HIVC phase. Enrolment into HIVC was associated with increased HC and condom use among HIV+ concordant [adjusted OR (adjOR)=3.03; 95% confidence interval (CI) 1.69–5.44 and adjOR=4.46, 95% CI 2.53–7.86, respectively], and serodiscordant couples (adjOR=2.21; 95% CI 1.25–3.92 and adjOR=4.75; 95% CI 2.89–7.82, respectively).

Key message points

- ▶ Few studies examine contraceptive use among couples from longitudinal studies, with most cross-sectional studies focusing on women alone.
- ▶ The present study in couples assessed over a 10-year period found that contraceptive use and dual use of hormonal contraception and condoms increased over time.
- ▶ Higher education and scaling-up of HIV care services were key determinants of contraceptive use among couples in the present study.
- ▶ In settings with overlapping rates of high fertility and HIV infection, integration of HIV and reproductive health services is critical.

Conclusions Use of modern contraception and dual method use increased over time, particularly after enrolment into HIVC. Integration of HIV and reproductive health services is critical for prevention of unwanted pregnancies and HIV infection.

INTRODUCTION

Sub-Saharan Africa (SSA) has the highest fertility rates in the world.¹ Low uptake of modern contraceptive methods with high levels of unmet need for family planning (FP) led to high rates of unplanned pregnancies in this region,¹ with an average total fertility rate (TFR) of 5.1 children per woman in SSA.² In

Uganda, the TFR is 6.2, with about 755 000 unplanned pregnancies per year.³ However the recent Demographic and Health Surveys (DHS) show a significant increase in modern contraceptive use from 18% in 2005/2006 to 26% in 2011, and a corresponding decline in the level of unmet need for FP (41% to 34%).^{3, 4} In Rakai district, South Western Uganda, similar trends in uptake of modern contraceptives (33% to 42%) and declines in unmet need for FP (35% to 29%) have been observed during the same period (Lutalo T, Trends and determinants of unmet need for modern contraceptives in Rakai, Uganda, personal communication, 2012).

These changes occurred in a generalised HIV epidemic. The high rates of HIV infection and fertility suggest that couples in developing countries need protection against HIV and sexually transmitted infections (STIs), as well as protection from unplanned pregnancies through use of effective contraception, including condoms that offer protection from HIV/STIs and pregnancy. It is estimated that 23.5 million people were living with HIV in SSA in 2011, the majority of whom were women of reproductive age.⁵ In Uganda the prevalence of HIV among adults 15–49 years is 7.1%,⁶ while in Rakai district it is estimated at 12%.⁷ Effective integration of HIV and reproductive health services is critical in settings with overlapping high rates of fertility and HIV prevalence.

The goal of this study was to examine levels and determinants of modern contraceptive use in a rural, resource-limited setting with high HIV prevalence, and substantial HIV care (HIVC) service provision. Although previous studies have been mainly cross-sectional and focused on female respondents only, this longitudinal study over an 11-year period used couples as the unit of analysis, and assessed the determinants of modern contraceptive use by couples' HIV status in Rakai, Uganda.

METHODS

The Rakai Health Sciences Program (RHSP) has followed individuals aged 15 to 49 years in an open cohort since 1994 in 50 rural villages through the Rakai Community Cohort Study (RCCS),⁸ in Rakai district, South-Western Uganda. Detailed socio-demographic, behavioural and sexual behaviour data were collected annually from consenting participants. Men and women were independently asked questions on the individual's or partner's use of contraception including permanent methods. HIV status was determined from venous blood using two different enzyme immunoassays (Vironostika[®] HIV-1, OrganonTeknika, Charlotte, NC, USA and Cambridge Biotech, Worcester, MA, USA), with Western blot (HIV-1 WB[®], Bio-Merieux–Vitek, St Louis, MO, USA) confirmation of all discordant EIAs and all HIV seroconverters.

Participants who wished to know their HIV serostatus received voluntary counselling and testing

(VCT)^{9, 10} as individuals or couples either in their home or at the RHSP community counselling facilities by a trained counsellor. The HIV counselling discussion included HIV prevention strategies such as abstinence, consistent use of condoms, couple counselling, partner disclosure, FP and prevention of mother-to-child HIV transmission (PMTCT). Free or subsidised condoms were provided to all individuals who wished to have them and referrals were provided for other modern contraceptive methods.

All participants testing HIV-positive were referred for HIVC at 17 RHSP clinics where they were evaluated for antiretroviral therapy (ART) eligibility [CD4 \leq 250 cells/mm³ or World Health Organization (WHO) Stage IV]. Although basic HIVC has been provided to all HIV-infected individuals, highly active antiretroviral therapy (HAART) has only been available since June 2004 through the President's Emergency Plan for AIDS Relief (PEPFAR). In addition to HAART, other services provided by the expanded HIVC services included FP for prevention of unwanted pregnancies, health and nutrition education, cotrimoxazole prophylaxis, insecticide-impregnated bed nets, and clean water vessels with hypochlorite disinfectant.

For this analysis, couples were the unit of analysis, and were retrospectively linked and categorised as concordantly HIV-negative (M–F–), concordantly HIV-infected (M+F+) and discordant (either M+F– or F+M–), where M and F indicate male and female, respectively. Information was obtained on each form of modern contraception, and injectables, pills and Norplant[®] were consolidated into one category of hormonal contraception (HC). Couples' use of contraception was categorised as (i) HC if HC use was reported by the female partner, (ii) use of condoms alone if mentioned by the male, but without female mention of HC and (iii) none if no modern methods were mentioned by either partner. A couple was coded with uptake of female-controlled method or male-controlled method if there was discrepancy in a couple member's report of a FP method. Dual use was defined as couples reporting concurrent condoms and HC use.

Covariates considered for the multivariate analysis included female age, duration since female partner receipt of VCT stratified as VCT within 30 days, VCT within 31–182 days, VCT within 183–365 days and VCT \geq 366 days prior to interview; couple's education categorised as 'none' if at most one partner had primary education, 'primary' if at most one had post-primary but both had at least primary education, or 'post-primary' if both had post-primary. Co-resident children were categorised as none, one to two, three to five, and six or more. Non-marital partners was defined as a respondent reporting a sexual relationship with someone to whom they were not officially married or in a consensual union either in the past 12 months or ongoing and was categorised as none, or any reported by the female-only, the male only, or

both. The HIVC periods were categorised as pre-HIVC before 2004, HIVC roll-out (2005–2007) and HIVC scale-up (2008–2011). Other variables controlled for in the multivariate analyses were socio-economic status (SES) based on the dwelling construction materials, with high SES if modern construction materials (iron/tiles, cement) were used, type of marriage (monogamous or polygamous) and religion.

Trends in the use of contraceptives over the three HIVC care periods were analysed using chi-square (χ^2) for trend, stratified by the couple's HIV status. To assess determinants of contraceptive use, multinomial logistic regression models were used to estimate odds ratios (ORs), and 95% confidence intervals (95% CIs) of HC use versus no modern methods, or use of condoms for FP versus no modern methods. Adjusted analyses included all variables in the univariate models with $p < 0.15$, potential confounders or variables with an OR ≥ 2.0 or ≤ 0.5 . We also adjusted for clustering at the couple level, because of multiple observations from the same couples, using sandwich robust

standard errors (SEs). We conducted a sub-analysis of couples with at least one HIV+ partner to estimate the effect of enrolment into HIVC by either one or both HIV+ partners. All statistical analyses were done using STATA software package V.12.0 (College Station, TX, USA).

The study was approved by Institutional Review Boards in Uganda (the Scientific and Ethics Committee of the Uganda Virus Research Institute, and the Uganda National Council of Science and Technology), and the USA (Western IRB, Olympia, Washington, and the Johns Hopkins University, School of Public Health).

RESULTS

A total of 6139 couples contributed 13 709 couple observations from the eight annual RHSP survey rounds conducted between March 2000 and June 2011. Of the couples in our analyses, 5083 (82.8%) were concordant HIV-negative, 481 couples (7.8%) concordant HIV+, 279 couples (4.5%) serodiscordant

Table 1 Demographic and use of voluntary counselling and testing and family planning services by couples, stratified by HIV status

Couples' characteristics	M–F– (n=11 566)	M+F+ (n=1033)	M–F+ (n=480)	M+F– (n=630)	p
Average age in years (SD)					
Male partner	34.1 (7.0)	35.5 (6.3)	34.7 (6.7)	36.8 (6.5)	<0.001
Female partner	28.6 (6.7)	30.0 (6.1)	29.9 (6.4)	30.9 (6.7)	<0.001
Highest schooling [n (%)]					
None	1008 (8.7)	118 (11.4)	60 (12.5)	61 (9.7)	
Primary	8917 (77.1)	799 (77.3)	376 (78.3)	500 (79.4)	<0.001
Post-primary	1641 (14.2)	116 (11.2)	44 (9.2)	69 (11.0)	
Non-marital relationships [n (%)]					
None	9200 (79.5)	814 (78.8)	388 (80.8)	487 (77.3)	
Female only	175 (1.5)	19 (1.8)	15 (3.1)	14 (2.2)	0.047
Male or both	2189 (18.9)	200 (19.4)	77 (16.0)	129 (20.5)	
Co-resident biological children [n (%)]					
0	867 (7.5)	157 (15.2)	82 (17.1)	78 (12.4)	
1–2	3996 (34.5)	397 (38.4)	211 (44.0)	204 (32.4)	<0.001
3–5	5230 (45.2)	427 (41.3)	166 (34.6)	272 (43.2)	
6+	1473 (12.7)	52 (5.0)	21 (4.4)	76 (12.1)	
Duration between VCT and interview (days) [n (%)]					
No VCT within 30 days	2056 (17.8)	251 (24.3)	118 (24.6)	118 (18.7)	
31–182	981 (8.5)	70 (6.8)	44 (9.2)	41 (6.5)	<0.001
183–365	1901 (16.4)	123 (11.9)	66 (13.8)	99 (15.7)	
366+	6628 (57.3)	589 (57.0)	252 (52.5)	372 (59.0)	
Stage of HIV programme roll-out [n (%)]					
Pre-HIV	3610 (31.2)	307 (29.7)	161 (33.5)	228 (36.2)	
Within first 2 years of implementation	2544 (22.0)	217 (21.0)	79 (16.5)	141 (22.4)	0.003
3+ years after initial implementation	5412 (46.8)	509 (49.3)	240 (50.0)	261 (41.4)	
Couple reported FP methods [n (%)]					
None	5597 (48.4)	352 (34.1)	204 (42.5)	230 (36.5)	
HC	3522 (30.5)	289 (28.0)	118 (24.6)	170 (27.0)	<0.001
Condoms	2447 (21.2)	392 (37.9)	158 (32.9)	230 (36.5)	

FP, family planning; HC, hormonal contraception; HIVC, HIV care; SD, standard deviation; VCT, voluntary counselling and testing.

where the male was HIV+ and 296 couples (4.8%) where the female was HIV+.

Table 1 summarises the couples' characteristics by HIV status. The *p* value in Table 1 is the association between couple HIV status and the various characteristics. HIV serodiscordant couples were significantly more likely to have no or primary education, whereas HIV-negative concordant couples were significantly more likely to have a post-primary education ($p < 0.001$). HIV-positive females (F+M-) and males (F-M+) in serodiscordant relationships were significantly more likely to report multiple sexual partners ($p < 0.001$). The average number of biological co-resident children was 3.04; this was higher when the female spouse was HIV-negative (M-F- or M+F-, $p < 0.001$). Overall, receipt of VCT in the past 31 days or more was high, 81.5%; M-F- couples 82.2% and M+F- 81.3%; but lower when the

female spouse was HIV+ in a concordant M+F+ (75.7%) or serodiscordant M-F+ couple (75.4%).

Overall, use of modern contraceptives was 53.0% (HC 29.9% and condoms 23.5%). The most commonly mentioned methods of modern contraceptives were injectables (23.1%), followed by condoms (16.3%), pills (5.2%) and Norplant (1.7%). Condoms use was higher when a couple member was HIV+ (M+F+ 37.9%; M-F+ 32.9%; M+F- 36.5%), relative to M-F- (21.2%), while injectables were more frequent among M-F- (30.5%).

Over the three HIVC periods, use of HC significantly increased from 22.9%, 31.3% and 33.9%, respectively (χ^2 for trend $p < 0.001$). These temporal increases were statistically significant in M-F- (23.2%, 31.2% and 34.8%, respectively; $p < 0.001$); and M+F+ (20.8%, 27.6% and 32.2%, respectively; $p = 0.005$); but not among discordant couples, (21.3%,

Table 2 Odds ratios of hormonal contraception and condom use among all couples

Parameter	Hormonal contraceptives				Condoms			
	HC-user/ total	HC-user/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)	Condom/ total	Condom/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)
Education								
None	194/984	19.7	1.00	1.00	263/1053	25.0	1.00	1.00
Primary	3160/8111	39.0	2.6 (2.12–3.18)	2.2 (1.78–2.72)	2481/7432	33.4	1.51 (1.24–1.83)	1.38 (1.13–1.68)
Post-primary	745/1387	53.7	4.73 (3.72–6.00)	3.4 (2.63–4.38)	483/1125	43.0	2.26 (1.79–2.85)	1.94 (1.52–2.49)
Non-marital relations								
None	3158/8998	35.1	1.00	1.00	1901/7731	24.6	1.00	1.00
Female only	86/169	50.9	1.91 (1.38–2.64)	2.02 (1.44–2.84)	54/137	39.4	2.0 (1.38–2.89)	1.92 (1.31–2.81)
Male or both	855/1324	64.6	3.37 (2.95–3.84)	3.33 (2.91–3.81)	1271/1740	73.1	8.31 (7.31–9.44)	8.61 (7.52–9.86)
Co-resident biological children								
0	158/904	17.5	1.00	1.00	280/1026	27.3	1.00	1.00
1–2	1348/3598	37.5	2.83 (2.30–3.48)	2.39 (1.91–2.98)	1210/3460	35.0	1.43 (1.20–1.70)	1.38 (1.13–1.67)
3–5	2091/4700	44.5	3.78 (3.07–4.66)	3.02 (2.42–3.78)	1395/4004	34.8	1.42 (1.20–1.69)	1.45 (1.19–1.76)
6+	502/1280	39.2	3.05 (2.39–3.89)	2.59 (1.98–3.40)	342/1120	30.5	1.17 (0.94–1.46)	1.45 (1.12–1.87)
Couple HIV								
M-F-	3522/9119	38.6	1.00	1.00	2447/8044	30.4	1.00	1.00
M+F+	289/641	45.1	1.3 (1.07–1.59)	1.57 (1.28–1.93)	392/744	52.7	2.55 (2.14–3.03)	3.08 (2.54–3.73)
M-F+	118/322	36.7	0.92 (0.70–1.21)	1.14 (0.87–1.50)	158/362	43.7	1.77 (1.38–2.28)	2.17 (1.65–2.86)
M+F-	170/400	42.5	1.17 (0.91–1.51)	1.4 (1.08–1.80)	230/460	50.0	2.29 (1.85–2.83)	2.76 (2.18–3.50)
Duration between most recent female VCT and interview (days)								
No VCT within 30 days	684/1961	34.9	1.0	1.0	582/1859	31.3	1.0	1.0
31–182	251/892	28.1	0.73 (0.61–0.88)	0.84 (0.69–1.02)	244/885	27.6	0.84 (0.70–1.00)	0.95 (0.78–1.16)
183–365	643/1682	38.2	1.16 (1.00–1.34)	1.18 (1.01–1.37)	507/1546	32.8	1.07 (0.92–1.24)	1.15 (0.98–1.36)
366+	2521/5947	42.4	1.37 (1.22–1.55)	1.13 (1.00–1.29)	1894/5320	35.6	1.21 (1.07–1.37)	1.15 (1.00–1.32)
Stage of HIVC programme roll-out								
Pre-HIVC	986/3393	29.1	1.00	1.00	913/3320	27.5	1.00	1.00
HIVC roll-out	935/2464	38.0	1.49 (1.34–1.66)	1.22 (1.09–1.38)	517/2046	25.3	0.89 (0.79–1.01)	0.83 (0.72–0.95)
HIVC scale-up	2178/4625	47.1	2.17 (1.96–2.41)	1.77 (1.58–1.99)	1797/4244	42.3	1.94 (1.74–2.15)	1.96 (1.73–2.22)

*Adjusted for socioeconomic status, religion, couple's difference in age (0–4, 5–9 or 10+ years), type of marriage (monogamous or polygamous). adjOR, adjusted odds ratio; CI, confidence interval; HC, hormonal contraception; HIVC, HIV care; OR, odds ratio; unadjOR, unadjusted odds ratio; VCT, voluntary counselling and testing.

36.4% and 25.0%, respectively; $p=0.32$). Use of condoms also increased overall, (21.2%, 17.3% and 28.0%, respectively; $p<0.001$) and among concordantly infected couples (30.3%, 24.4% and 48.0%, respectively; $p<0.001$), and serodiscordant couples, (24.2%, 22.7% and 48.7%, respectively; $p<0.001$), but not among concordant HIV-negative couples (28.1%, 16.3% and 24.2%; $p<0.001$). Dual use of HC and condoms was reported by both females and males (3.7% and 8.3%, respectively; $p<0.001$). Over the three HIVC periods, dual use increased overall for both females (0.7%, 1.78% and 6.63%; $p<0.001$) and males (5.3%, 6.4% and 11.5%; $p<0.001$) and this increase was seen irrespective of HIV status.

In addition to the variables summarised in Table 1, about three-quarters of the couples were Christians, were in a monogamous union and most couples were either in the high or the middle SES category, but no significant differences were observed by couples' HIV status.

Table 2 summarises determinants of contraceptive use among all couples in our study. Factors significantly associated with increased use of HC and

condoms included higher levels of education, reported non-marital relations by the female, male or both, and having any co-resident biological children. When stratified by HIV status, HC use was higher among couples where the male was HIV-positive (M+F+ or M+F-) whereas condom use was higher if at least one member was HIV-positive relative to concordant negative couples. Duration of 6 months or more since receipt of VCT by the female partner was also associated with increased use of HC, as was HIV roll-out adjOR=1.22 (95% CI 1.09–1.38) and scale-up adjOR=1.77 (95% CI 1.58–1.99) relative to the pre-HIVC period. Use of condoms increased with duration since receipt of VCT of 1 year or more, as well in the HIVC scale-up (adjOR=1.96, 95% CI 1.73–2.22), whereas there was a decrease in condom use during the HIVC roll-out period.

In order to assess the effect of enrolment into HIVC, a sub-analysis was conducted among concordant HIV-positive couples (Table 3). Factors associated with increased HC use were the male's report of non-marital partners, having any co-resident biological children, and both partners being enrolled into HIVC.

Table 3 Odds ratios of hormonal contraception and condom use among HIV-positive concordant couples

Parameter	Hormonal contraceptives				Condoms			
	HC-user/ total	HC-user/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)	Condom/ total	Condom/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)
Education								
None	25/71	35.2	1.00	1.00	47/93	50.5	1.00	1.00
Primary	231/501	46.1	1.57 (0.87–2.85)	1.44 (0.77–2.70)	298/568	52.5	1.08 (0.66–1.76)	0.91 (0.53–1.56)
Post-primary	33/69	47.8	1.69 (0.77–3.71)	1.46 (0.62–3.43)	47/83	56.6	1.28 (0.66–2.47)	1.09 (0.52–2.28)
Non-marital relations								
None	224/537	41.7	1.00	1.00	277/590	47.0	1.00	1.00
Female only	5/15	33.3	0.70 (0.22–2.24)	0.77 (0.23–2.62)	4/14	28.6	0.45 (0.14–1.49)	0.55 (0.15–2.04)
Male or both	60/89	67.4	2.89 (1.79–4.67)	3.69 (2.18–6.26)	111/140	79.3	4.33 (2.77–6.76)	6.05 (3.62–10.10)
Co-resident biological children								
0	20/103	19.4	1.00	1.00	54/137	39.4	1.00	1.00
1–2	107/260	41.2	2.90 (1.57–5.37)	3.21 (1.62–6.37)	137/290	47.2	1.38 (0.88–2.15)	1.51 (0.90–2.54)
3–5	141/243	58.0	5.74 (3.06–10.76)	6.02 (2.97–12.17)	184/286	64.3	2.77 (1.75–4.38)	3.08 (1.80–5.27)
6+	21/35	60.0	6.23 (2.25–17.22)	5.19 (1.68–15.98)	17/31	54.8	1.87 (0.63–5.54)	1.64 (0.55–4.90)
Couple enrolment into HIVC								
None or within 30 days	190/478	39.8	1.0	1.0	190/478	39.8	1.0	1.0
Only one in care	73/106	68.9	2.80 (1.62–4.84)	1.71 (0.93–3.13)	73/106	68.9	3.35 (2.02–5.57)	2.34 (1.29–4.22)
Both in HIV care	129/160	80.6	4.62 (2.80–7.61)	3.03 (1.69–5.44)	129/160	80.6	6.31 (3.90–10.19)	4.46 (2.53–7.86)
Stage of HIVC programme roll-out in community								
Pre-HIVC	93/242	38.4	1.0	1.0	93/242	39.4	1.0	1.0
HIVC roll-out	53/157	33.8	1.32 (0.87–2.02)	0.93 (0.58–1.50)	53/157	33.8	0.82 (0.53–1.27)	0.51 (0.32–0.83)
HIVC scale-up	246/345	71.3	3.80 (2.48–5.81)	2.13 (1.23–3.69)	246/345	71.3	3.98 (2.67–5.93)	1.82 (1.10–3.00)

*Adjusted for socioeconomic status, religion, couple's difference in age (0–4, 5–9 or 10+ years), type of marriage (monogamous or polygamous). adjOR, adjusted odds ratio; CI, confidence interval; HC, hormonal contraception; HIVC, HIV care; OR, odds ratio; unadjOR, unadjusted odds ratio.

HIVC scale-up was also associated with increase in HC use (adjOR=2.13; 95% CI 1.23–3.69). Condom use increased with male report of non-marital partners, having any co-resident biological children, either or both partners being enrolled into HIVC and the expanded HIVC phase (adjOR=1.82, 95% CI 1.1–3.0). Again, the roll-out phase of HIVC was associated with a decrease in condom use.

Table 4 summarises the odds of HC and condom use among HIV serodiscordant couples.

HC use was higher with higher education levels, report of a non-marital partner by either spouse, any co-resident biological children, and when the HIV+ spouse was enrolled in HIVC (adjOR=2.21, 95% CI 1.25–3.92).

Increased use of HC was observed during the HIV care roll-out and scale-up periods. Use of condoms significantly increased with post-primary education, male spouse report of non-marital partners, having more than three co-resident biological children, and almost five-fold higher odds of condom use if the HIV+ partner was enrolled in HIVC. Expanded HIVC was also associated with an increase in condom use.

Being of low or middle SES relative to high SES was associated with decreased use of HCs and condoms, irrespective of the HIV status of the couple.

Figure 1 summarises the impact of roll-out and scale-up of HIVC on contraceptive use. HC increased steadily during all the three HIVC periods among the concordant M–F– and M+F+. However, a decline in HC was observed during the scale-up period among discordant couples (M–F+, M+F–) at the time when use of condoms increased among these couples. Although use of condoms declined between the pre-HIVC and HIV-roll-out at a time when HC use increased, there was an overall increase in condom use between HIVC roll-out and scale-up periods.

DISCUSSION

Few studies prospectively assess contraceptive use among couples, despite changes in contraceptive use over time and the significant role of males in contraceptive decision-making. We longitudinally assessed contraceptive use among couples in Rakai, Uganda, adjusting for HIV-associated risk factors and HIV serostatus. Overall, almost half the couples in our study

Table 4 Odds ratios of hormonal contraception and condom use among HIV serodiscordant couples

Parameter	Hormonal contraceptives				Condoms			
	HC-user/ total	HC-user/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)	Condom/ total	Condom/ total (%)	UnadjOR (95% CI)	AdjOR* (95% CI)
Education								
None	14/74	18.9	1.0	1.0	47/107	43.9	1.0	1.0
Primary	242/581	41.7	3.06 (1.60–5.84)	2.90 (1.45–5.79)	295/634	46.5	1.11 (0.66–1.87)	1.44 (0.79–2.64)
Post-primary	32/67	47.8	3.92 (1.69–9.11)	3.50 (1.42–8.60)	46/81	56.8	1.68 (0.80–3.50)	2.61 (1.14–6.00)
Non-marital relations								
None	213/609	35.0	1.0	1.0	266/662	40.2	1.0	1.0
Female only	13/19	68.4	4.03 (1.46–11.08)	4.62 (1.51–14.11)	10/16	62.5	2.48 (0.95–6.47)	2.38 (0.79–7.15)
Male or both	62/94	66.0	3.60 (2.22–5.85)	3.59 (2.18–5.91)	112/144	77.8	5.21 (3.36–8.09)	7.10 (4.38–11.49)
Co-resident biological children								
0	16/110	14.6	1.0	1.0	50/144	34.7	1.0	1.0
1–2	107/280	38.2	3.63 (1.86–7.11)	3.03 (1.53–6.00)	135/308	43.8	1.47 (0.90–2.40)	1.44 (0.82–2.54)
3–5	141/275	51.3	6.18 (3.16–12.10)	4.76 (2.38–9.52)	163/297	54.9	2.29 (1.41–3.70)	1.85 (1.05–3.07)
6+	24/57	42.1	4.27 (1.84–9.93)	4.06 (1.56–10.57)	40/73	54.8	2.28 (1.19–4.35)	2.51 (1.10–5.70)
Couple HIV status								
M–F+	118/322	36.7	1.0	1.0	158/362	43.7	1.0	1.0
M+F–	170/400	42.5	1.28 (0.89–1.84)	1.34 (0.90–1.99)	230/460	50.0	1.29 (0.94–1.78)	1.38 (0.94–2.04)
Couple enrolment into HIVC								
HIV+ not in care/within 30 days	221/605	36.5	1.0	1.0	222/606	36.6	1.0	1.0
HIV+ spouse in care	67/117	57.3	2.33 (1.45–3.74)	2.21 (1.25–3.92)	166/216	76.9	5.74 (3.82–8.62)	4.75 (2.89–7.82)
Stage of HIVC programme roll-out in community								
Pre-HIVC	83/295	28.1	1.0	1.0	94/306	30.7	1.0	1.0
HIVC roll-out	80/170	47.1	2.27 (1.49–3.46)	1.86 (1.20–2.90)	50/140	35.7	1.25 (0.82–1.91)	0.97 (0.61–1.54)
HIVC scale-up	125/257	48.6	2.42 (1.62–3.62)	1.79 (1.12–2.88)	244/376	64.9	4.17 (2.92–5.95)	2.39 (1.52–3.74)

*Adjusted for socioeconomic status, religion, couple's difference in age (0–4, 5–9 or 10+ years), type of marriage (monogamous or polygamous). adjOR, adjusted odds ratio; CI, confidence interval; HC, hormonal contraception; HIVC, HIV care; OR, odds ratio; unadjOR, unadjusted odds ratio.




Figure 1 Trends in couples' hormonal contraception (HC) and condom use by HIV care (HIVC) roll-out period.

reported using HC or condoms, and as reported in other studies,^{11–12} contraceptive use increased over time. Both HC and condom use increased significantly as HIVC was being scaled-up in the communities, and among couples where at least one member was HIV-positive, enrolment into HIVC was also associated with a significant increase in HC and condom use.

Several studies have assessed determinants of modern contraceptive use.^{11–15} Our findings are consistent with other studies that report contraceptive use is higher among the more educated.^{13–15} However, we observed no impact of education on contraceptive use among HIV-positive concordant couples. Potentially, knowledge of HIV status and the desire to prevent infant infection mitigated the education effect among HIV-positive concordant couples. As with other studies,¹⁶ number of co-resident children was strongly associated with use of contraception and highlights the importance of promoting long-term effective methods for couples with two or more children, given the persistently high TFR in Uganda.^{18–21} Couples reporting extramarital relationships were motivated to use HC or condoms, especially if the male reported extramarital relationships, potentially to reduce the risk of both HIV and unwanted pregnancies when engaging in high-risk behaviours.

A longitudinal study of serodiscordant couples from seven southern and east African countries found an increase in HIV acquisition and transmission among serodiscordant couples where the woman was using HC, particularly depot medroxyprogesterone acetate.²² However, the current WHO guidelines

recommend that women at high risk for HIV infection can use HC without restriction, but advise concomitant use of condoms.²³ The use of HC, and especially injectable contraceptives, is gaining popularity in SSA, especially among young women.²⁴ In Uganda, the latest DHS reported that approximately 34% of women reported ever-use of HC.²⁵ The significant temporal increase of HC use, particularly injectables among HIV-positive concordant and serodiscordant couples in our cohort, demonstrates the increasing popularity of injectable contraceptives to space or limit fertility.

Among couples where one or both partners were HIV-positive, over half (53%) were in serodiscordant relationships. Given the high rates of HIV transmission among serodiscordant couples, ranging from 2.0 to 11.8/100 person years,^{26–28} and that almost 20% of couples in concordant HIV-positive relationships report extramarital relationships, condom use needs to be vigorously promoted to prevent HIV transmission. Dual use of HC and condoms among couples increased significantly over time, irrespective of the HIV status of the couple, but still is infrequently practised.

All HIV-positive individuals who received HIV-positive results were counselled and invited to enrol into the Rakai HIV Care services.²⁹ Enrolment of the HIV-positive spouse into HIVC resulted in an increase in HC and condom use among serodiscordant HIV-positive concordant couples. This demonstrates the importance of promoting contraceptive use in HIVC programmes, which can be important venues to integrate reproductive health and FP messages.

A limitation of this study is that contraceptive use of the partner was self-reported but there was no specific information on which partner the respondent was referring to, especially with individuals who reported multiple sexual partners.

CONCLUSIONS

Prevention of HIV and unwanted pregnancies among couples requires a combination of strategies, including counselling about consistent condom use, contraceptive use, ART and pre-exposure prophylaxis for prevention of transmission to the uninfected partner and ART for prevention of PMTCT. Use of contraceptives among couples in our study increased over time, especially during the expanded HIVE programme in this community. Enrolment into HIVE was a determinant of HC and condom use, and there is a need for integration of HIV and reproductive health services so as to reduce the burden of HIV/STIs and unwanted pregnancies among women in developing countries.

Author affiliations

¹Assistant Professor, Department of Population, Reproductive and Family Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

²Lecturer, Makerere University, School of Public Health, Kampala, Uganda and Associate Professor, Population, Reproductive and Family Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

³Senior Researcher, Rakai Health Science Program, Entebbe, Uganda

⁴Statistician, Rakai Health Science Program, Entebbe, Uganda

⁵Professor, Makerere University, School of Public Health, Kampala, Uganda

⁶Professor, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

⁷Professor, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Funding National Institutes of Health (NINR: 5R01NR011474-03), Bill and Melinda Gates Foundation, Grant # 22006.03, Grants #U1AI51171 and 1U01AI075115-01A1 from the National Institutes of Health, Division of Allergy and Infectious Diseases.

Competing interests None.

Ethics approval This study was approved by Institutional Review Boards in Uganda (the Scientific and Ethics Committee of the Uganda Virus Research Institute, and the Uganda National Council of Science and Technology), and the USA (Western IRB, Olympia, Washington, and the Johns Hopkins University, School of Public Health).

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different

terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- 1 World Bank. *World Development Indicators*. Washington, DC: World Bank; 2009.
- 2 United Nations Population Division. *World Contraceptive Use*. New York: United Nations Department of Economic and Social Affairs; 2009.
- 3 Statistics Department Ministry of Finance and Economic Planning. *Uganda Demographic and Health Survey: 2011*. Calverton, MD, USA: Macro International Inc.; 2012.
- 4 Statistics Department Ministry of Finance and Economic Planning. *Uganda Demographic and Health Survey: 2005/6*. Calverton, MD, USA: Macro International Inc.; 2007.
- 5 UNAIDS. *AIDS Epidemic Update*. Geneva, Switzerland: UNAIDS; 2011.
- 6 Minister of Health U. *Uganda AIDS Indicator Survey 2011*. Kampala, Uganda: Minister of Health; 2012.
- 7 Trends in HIV Rates, Behaviors, and Use of Interventions in a Population-based Cohort: Rakai, Uganda, 1994 to 2010. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2012.
- 8 Wawer MJ, Sewankambo NK, Serwadda D, *et al*. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group [see comments]. *Lancet* 1999;353:525–535.
- 9 Makumbi F, Nakigozi G, Lutalo T, *et al*. Use of HIV-related services and modern contraception among women of reproductive age, Rakai, Uganda. *Afr J Reprod Health* 2010;14:91–101.
- 10 Matovu JK, Kigozi G, Nalugoda F, *et al*. The Rakai Project counselling programme experience. *Trop Med Int Health* 2002;7:1064–1067.
- 11 Heffron R, Were E, Celum C, *et al*. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. *Sex Transm Dis* 2010;37:621–628.
- 12 Stephenson R, Vwalika B, Greenberg L, *et al*. A randomized controlled trial to promote long-term contraceptive use among HIV-serodiscordant and concordant positive couples in Zambia. *J Womens Health (Larchmt)* 2011;20:567–574.
- 13 Agyei WK, Migadde M. Demographic and sociocultural factors influencing contraceptive use in Uganda. *J Biosoc Sci* 1995;27:47–60.
- 14 Eisenberg DL, Allsworth JE, Zhao Q, *et al*. Correlates of dual-method contraceptive use: an analysis of the national survey of family growth (2006–2008). *Infect Dis Obstet Gynecol* 2012;2012:717163.
- 15 Magadi MA, Curtis SL. Trends and determinants of contraceptive method choice in Kenya. *Stud Fam Plann* 2003;34:149–159.
- 16 Wang C. Trends in contraceptive use and determinants of choice in China: 1980–2010. *Contraception* 2011; 85:570–579.
- 17 Calazans G, Araujo TW, Venturi G, *et al*. Factors associated with condom use among youth aged 15–24 years in Brazil in 2003. *AIDS* 2005;19(Suppl. 4):S42–S50.
- 18 Uganda Bureau of Statistics (UBOS), ORC Macro. *Uganda-Demographic and Health Survey 2000–2001*. Calverton, MD: UBOS and ORC Macro; 2001.
- 19 Uganda Bureau of Statistics (UBOS), Macro International Inc. *Uganda Demographic and Health Survey, 2006*. Calverton, MD, USA: UBOS and Macro International Inc.; 2007.

- 20 Uganda Bureau of Statistics (UBOS), ORC Macro. *Uganda Demographic and Health Survey, 1988–89*. Calverton, MD: UBOS and ORC Macro; 1990.
- 21 Uganda Bureau of Statistics (UBOS), ORC Macro. *Uganda Demographic and Health Survey, 1995*. Calverton, MD: UBOS and ORC Macro; 1997.
- 22 Heffron R, Donnell D, Rees H, *et al.* Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. *Lancet Infect Dis* 2012;12:19–26.
- 23 World Health Organization. *Hormonal Contraception and HIV: Technical Statement*. 2012. http://whqlibdoc.who.int/hq/2012/WHO_RHR_12.08_eng.pdf [accessed 10 May 2013].
- 24 Creanga AA, Gillespie D, Karklins S, *et al.* Low use of contraception among poor women in Africa: an equity issue. *Bull World Health Organ* 2011;89:258–266.
- 25 Department of Health MRC. *South Africa Demographic and Health Survey 2003*. Pretoria, South Africa: OrcMacro; 2007.
- 26 Celum C, Wald A, Lingappa JR, *et al.* Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med* 2010;362:427–439.
- 27 Quinn TC, Wawer MJ, Sewankambo N, *et al.* Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N Engl J Med* 2000;342:921–929.
- 28 Gray RH, Kiwanuka N, Quinn TC, *et al.* Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. *AIDS* 2000;14:2371–2381.
- 29 Nakigozi G, Makumbi F, Reynolds S, *et al.* Non-enrollment for free community HIV care: findings from a population-based study in Rakai, Uganda. *AIDS Care* 2011;23:764–770.